Peer-Reviewed Results of Haemonetics' Improving Plasma Collection (IMPACT) Trial Published in the Journal TRANSFUSION
IMPACT compared plasma collection using NexSys PCS® with YES® Technology, which collects plasma based on a donor's weight per the current industry standard nomogram, to collection with NexSys PCS® with Persona® Technology which uses a novel, personalized Percent Plasma Nomogram (PPN) based on body mass index (BMI) and hematocrit, to enable a more tailored collection target. The trial found that the personalized donation method has a non-inferior safety profile, and demonstrated a yield increase of +8.2% more plasma per collection on average as compared to the control, based on the donor population in the trial. Based on the results of the IMPACT trial, Haemonetics' NexSys PCS® system with Persona® Technology received
"Plasma is a critical ingredient for important medicines that can have a life-changing impact on patients suffering from hundreds of conditions including primary immunodeficiency, hemophilia, trauma and more," said
According to the
The full publication, "Personalized collection of plasma from healthy donors: A randomized controlled trial of a novel technology-enabled nomogram," can be accessed in the
About NexSys PCS® with Persona® Technology
The NexSys PCS® plasma collection system with Persona® Technology is intended for use as an automated cell separator system and blood component collector in conjunction with single-use sterile disposable sets, with or without saline compensation. Products that can be collected using the NexSys PCS® system include source plasma and plasma for transfusion. The Persona® Technology builds on NexSys PCS® with YES® Technology, which received FDA 510(k) clearance in 2018 and has been used to perform millions of collections to date and has been in extensive clinical use ever since. The NexSys PCS® system with Persona® Technology includes disposables and the ability to integrate with NexLynk DMS® donor management system. Visit www.nexsyspcs.com to learn more.
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
Cautionary Statement Regarding Forward-Looking Information
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding plans and objectives of management for the operation of Haemonetics, including statements regarding potential benefits associated with the NexSys PCS® system with Persona® Technology, and Haemonetics' plans or objectives related to the development and commercialization of this product. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon Haemonetics' current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences.
Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, product quality; market acceptance; the effect of economic and political conditions; the impact of the COVID-19 pandemic, including the scope and duration of the pandemic, government actions and restrictive measures implemented in response; the impact of competitive products and pricing; blood product reimbursement policies and practices; and the effect of industry consolidation as seen in the plasma market. These and other factors are identified and described in more detail in the Company's periodic reports and other filings with the
View original content to download multimedia:http://www.prnewswire.com/news-releases/peer-reviewed-results-of-haemonetics-improving-plasma-collection-impact-trial-published-in-the-journal-transfusion-301280044.html